Brief: MaxCyte Enters Into A Non-Exclusive, Clinical & Commercial License Agreement
14/11/2018 07:53
Nov 14 (Reuters) - MaxCyte Inc MXCT.L :
* ENTERED INTO A NON-EXCLUSIVE, CLINICAL AND COMMERCIAL
LICENSE
AGREEMENT
* AGREEMENT ALLOWS PRECISION TO USE CO'S FLOW
ELECTROPORATION
TECHNOLOGIES TO DELIVER PRECISION'S PROPRIETARY ARCUS
GENOME-EDITING TECHNOLOGY
Source text for Eikon: ID:nRSN2611Ha
Further company coverage: MXCT.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MaxCyte
See all newsMaxCyte, Inc. MaxCyte, Inc. - MXCR - Second Price Monitoring Extn
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Price Monitoring Extension
Brief: Maxcyte And Allogene Therapeutics Sign Clinical And Commercial License Agreement To Enable The Advancement Of Allogeneic Car T (Allocar T™) Therapies
Brief: Maxcyte Signs Agreement With KSQ Therapeutics
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Agreement with KSQ Therapeutics